RESEARCH STUDY
Were you diagnosed with Relapsed or Refractory Multiple Myeloma? Has the disease come back, even after multiple treatments?
Explore your options. Consider participating in the Kilimanjaro study.
About
relapsed or refractory multiple myeloma
Multiple myeloma is a cancer that affects a type of white blood cell, called a plasma cell, that helps the immune system fight infections. Sometimes, cancer will respond to treatment but then become resistant to the treatment and start growing again. When this happens with multiple myeloma, it is called Relapsed or Refractory Multiple Myeloma 1.
Currently, there are few treatment options for people with relapsed or refractory multiple myeloma. Approved treatments may include medications that can slow how fast the myeloma cells multiply, medications that block how fast myeloma can grow and medications that can help the immune system fight the myeloma 1.
 1 Watson, S. (2021, April 21). Refractory multiple myeloma. WebMD. Retrieved October 13, 2022, from https://www.webmd.com/cancer/multiple-myeloma/refractory-multiple-myeloma
Our Study
An investigational drug combination is being studied for use in patients who have relapsed or refractory multiple myeloma. The investigational drug is not approved by the United States Food and Drug Administration (FDA), or any other global regulatory agency and the safety and activity are under evaluation.
Our investigational drug, called ABBV-383, is being studied in patients with relapsed or refractory multiple myeloma to determine if it is safe and effective when given via an intravenous infusion with standard of care anti-myeloma treatments.
The purpose of the Kilimanjaro study is to compare the investigational drug in various dosages, when combined with other approved treatments for multiple myeloma, to determine if anti-tumor activity seen with these medications is enhanced with ABBV-383. In the Kilimanjaro study, participants will be assigned to receive the investigational drug in combination with either a standard anti-multiple myeloma therapy or another investigational therapy. Study participants will be followed closely with clinic visits and tests.
There are important criteria that you must meet to be eligible to participate in Kilimanjaro. The following highlights a few key eligibility criteria:
- You must be 18 years of age or older
- You must have been diagnosed with relapsed or refractory multiple myeloma
- You must have tried at least 3 courses of treatment for your multiple myeloma in the past
- You do not need chemotherapy to treat other forms of cancer
- You do not have an active, systemic infection including COVID-19, HIV, Hepatitis B or Hepatitis C
- You are not currently enrolled in another clinical study
To determine if you meet all eligibility criteria and may be a candidate to participate in Kilimanjaro, you will need to be evaluated by a study physician (principal investigator).
Locations
Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin
University of Washington
Seattle, Washington
Huntsman Cancer Institute
Salt Lake City, Utah
University of Texas Southwestern Medical Center
Dallas, Texas
Levine Cancer Institute
Charlotte, North Carolina
Memorial Sloan Kettering Cancer Center
New York, New York
Rutenberg Cancer CenterÂ
New York, New York
The Valley Hospital
Paramus, New Jersey
University of Michigan Comprehensive Cancer Center Michigan Medicine
Ann Arbor, Michigan
University of Massachusetts – Worcester
Worcester, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Maryland School of Medicine
Baltimore, Maryland
Moffitt Cancer Center
Tampa, Florida
Sylvester Comprehensive Cancer Center
Miami, Florida
University of Arkansas for Medical Sciences
Little Rock, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Sylvester Comprehensive Cancer Center
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
University of Maryland School of Medicine
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Massachusetts - Worcester
Worcester, Massachusetts
University of Michigan Comprehensive Cancer Center Michigan Medicine
Ann Arbor, Michigan
The Valley Hospital
Paramus, New Jersey
Rutenberg Cancer CenterÂ
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
University of Texas Southwestern Medical Center
Dallas, Texas
Huntsman Cancer Institute
Salt Lake, Utah
University of Washington
Seattle, Washington
Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin
Do I Qualify?
In order to see if you might be eligible, we need to ask you some quick questions. If you pre-qualify, you can submit your contact information to the local study center. The study coordinator will then contact you to tell you more about the study, answer your questions and possibly schedule a visit to the research center.
If you are answering these questions on behalf of the person with multiple myeloma, please provide responses from their perspective (i.e., provide their date of birth, etc.)
Frequently Asked Questions
Patients have different reasons for participating in clinical research, including:
- Contributing to the advancement of science
- Gaining access to investigational medications or study procedures that otherwise would be unavailable options.
You will first go through a screening process at the study site. If you are eligible for the Kilimanjaro study, you will be assigned to receive one of the following treatment options:
- ABBV-383 + pomalidomide-dexamethasone
- ABBV-383 + lenalidomide-dexamethasone
- ABBV-383 + daratumumab-dexamethasoneÂ
- ABBV-383 + nirogacestat (Another investigational agent)
Post-treatment information will be collected every 12 weeks for approximately 1 year post study completion.
You may qualify to participate if you meet the following requirements:
- You must be 18 years of age or older
- You must have been diagnosed with relapsed or refractory multiple myeloma
- You must have tried at least 3 courses of treatment for your multiple myeloma in the past
- You do not need chemotherapy to treat other forms of cancer
- You do not have an active, systemic infection including COVID-19, HIV, Hepatitis B or Hepatitis C
- You are not currently enrolled in another clinical study
Additional study criteria will apply.
Study participants are expected to attend all clinic visits and complete all study procedures according to the study doctor’s instructions to ensure we can understand how the treatment is working.  You may receive reimbursement for study-related costs and expenses. The study team can provide more details if you do qualify and are considering participation.
Your participation in the study is voluntary—you can stop participating at any time for any reason without any penalty or loss of benefits to which you may otherwise be entitled.